

# Impaired rejection and mucosal injury of small intestinal allografts lacking the interferon- $\gamma$ receptor

ANDREW M. VEITCH\*, LISA M. HIGGINS†, MONA  
BAJAJ-ELLIOT\*, MICHAEL J. G. FARTHING\* AND THOMAS  
T. MACDONALD†

*\*Digestive Diseases Research Centre, St Bartholomew's and the Royal London School of  
Medicine and Dentistry, London UK, and †Paediatric Gastroenterology Department,  
St Bartholomew's and the Royal London School of Medicine & Dentistry, London UK*

Received for publication 9 August 2002

Accepted for publication 30 April 2003

**Summary.** Small intestinal mucosal T cell activation results in villous atrophy and crypt hyperplasia. There is conflicting evidence as to whether a Th1 IFN- $\gamma$  response may be involved. Using a murine intestinal transplant model of T cell-mediated enteropathy we aimed to study the role of IFN- $\gamma$  on the development of villous atrophy and crypt hyperplasia. Isografts or allografts of foetal small intestine from 129SV-/- IFN- $\gamma$  receptor knockout mice or wild type mice were implanted under the kidney capsule of Balb/c recipient mice. Grafts were examined histologically at intervals from 2 to 9 days post implantation for signs of rejection. Quantitative rtPCR for IFN- $\gamma$ , TNF $\alpha$  and IL-4 was conducted on grafts at 5 and 9 days post implantation. In allografts, rejection accompanied by the development of villous atrophy and crypt hyperplasia, occurred in a time-dependent manner. However this process was markedly slower in the IFN- $\gamma$  receptor knockout grafts compared to the wild type grafts at 5 days ( $\chi^2 = 10.08$ ,  $P = 0.007$ ) and 9 days post implantation ( $\chi^2 = 13.25$ ,  $P = 0.004$ ). There were also significantly fewer TNF $\alpha$  transcripts in allografts of IFN- $\gamma$  -/- intestine than in wild type allografts ( $P = 0.02$ ). IFN- $\gamma$  has a partial, but not obligatory, role in the development of villous atrophy and crypt hyperplasia during T cell mediated rejection of intestinal allografts.

**Keywords:** interferon gamma, tumour necrosis factor alpha, allograft, intestine, murine

Correspondence: A.M. Veitch, Department of Gastroenterology, New Cross Hospital, Wolverhampton, WV10 0QP, UK.  
Tel.: +44 (0) 1902 644918, Fax: +44 (0) 1902 642935, E-mail:  
Dr.Veitch@rwh-tr.nhs.uk

*Ex vivo* and animal studies support the hypothesis that activated lamina propria T cells are pivotally involved in the pathogenesis of villous atrophy and crypt hyperplasia (enteropathy) (Guy-Grand & Vassalli 1986; Lionetti *et al.* 1993; Wakelin *et al.* 1994; Maric *et al.* 1996). T cell activation has been demonstrated in the small intestinal mucosa of untreated coeliac disease (Halstensen *et al.* 1993), and this is associated with a Th1 IFN- $\gamma$  response (Kontakou *et al.* 1994). Studies in a human foetal intestinal explant model have demonstrated that direct stimulation of lamina propria T cells can result in either villous atrophy/crypt hyperplasia or complete mucosal destruction that is prevented by inhibition of T cell activation (MacDonald & Spencer 1988; Ferreira *et al.* 1990; Lionetti *et al.* 1993). Although Th1 responses in this model are important in the genesis of the lesions, the final effector molecules of mucosal change are growth factors and matrix metalloproteinases released by cytokine activated gut stromal cells (Bajaj-Elliott *et al.* 1997, 1998; Pender *et al.* 1996, 1997).

The role of interferon- $\gamma$  in gut diseases is still not clear. Although numbers of CD4 cells secreting this cytokine are invariably elevated in animal models of inflammatory bowel disease (Strober *et al.* 1998; Fish *et al.* 1999), some studies have suggested that gut damage is actually worse in the absence of interferon- $\gamma$  (IFN- $\gamma$ ) (Dohi *et al.* 1999).

Transplantation of genetically incompatible tissues into immunocompetent recipients invariably leads to tissue rejection, a process known to be T cell mediated. Allografts of murine foetal gut implanted under the kidney capsule of recipient mice are rejected in a time-dependent fashion in a predictable way that varies according to which combinations of strains of mice are used (Ferguson & Parrott 1972; 1973; Elves & Ferguson 1975). During the rejection process the morphology of the grafts changes from essentially normal with tall villi, and short crypts, to partial villous atrophy and crypt hyperplasia, and eventual tissue destruction. Since the role of IFN- $\gamma$  in this model is not known, and since generally the role of IFN- $\gamma$  in enteropathy has not been resolved, we have used allografts of foetal intestine from IFN- $\gamma$  receptor knockout mice to directly assess whether IFN- $\gamma$  has a direct effect on transplanted tissue during the rejection process.

## Materials and methods

### Animals

Six to eight weeks old mice, weighing at least 20 g were used. Timed-mated pregnant female 129SV $^{+/+}$  mice

were purchased from Harlan, UK. A stock of 129SV $^{-/-}$  IFN- $\gamma$  receptor knockout mice was maintained in the Biological Services Unit at St. Bartholomew's and the Royal London School of Medicine and Dentistry.

### Grafts

Allogeneically mismatched donors and recipients were used to study the rejection process. Donor 129SV mice are of the H-2<sup>b</sup> haplotype and Balb/c mice are H-2<sup>d</sup>. 129SV $^{+/+}$  wild type grafts and 129SV $^{-/-}$  'IFN- $\gamma$  receptor knockout' foetal grafts were implanted into adult allogenic Balb/c recipients (39 mice 129SV $^{+/+}$  Balb/c, 18 mice 129SV $^{-/-}$  Balb/c). 129SV $^{-/-}$  isografts were also implanted (13 mice). The time course of rejection with these combinations of strains of mice was determined by harvesting grafts at intervals following implantation (Ferguson & Parrott 1973).

Foetal gut was obtained and implanted under the kidney capsule of recipient mice as previously described (Ferguson & Parrott 1972). One graft was implanted under the capsule of each kidney. Grafts were retrieved from recipient mice from 2 to 9 days after implantation. From each mouse, one graft was stored for histological examination, and one for rtPCR cytokine analysis. Samples were stored at  $-70^{\circ}\text{C}$ .

Snap-frozen grafts were cryostat-cut into 5  $\mu\text{m}$  sections, mounted on poly L-lysine coated glass slides and stained with haematoxylin and eosin. Histological changes within the grafts were graded according to the classification of Ferguson and Parrott in which the degree of mucosal injury varied from none ('normal') to complete destruction ('submucosa') (Ferguson & Parrott 1973). Intermediate grades 'L+', 'L++', and 'flat' indicated lamina propria lymphocytic infiltration, reduction in villous height, and subtotal villous atrophy with crypt hyperplasia, respectively.

### Graft cytokine expression

Quantitative rtPCR was performed as previously described (Eckmann *et al.* 1996). In brief, RNA was extracted from biopsies using a monophasic solution of phenol and guanidine isothiocyanate and chloroform, followed by isopropyl precipitation. Serial dilutions of standard RNA were co-reverse transcribed with target RNA. Standard RNA was derived from plasmids encoding primer sequences for all of the cytokines studied. A mixture of four plasmids, pMCQ1, pMCQ2, pMCQ3, and pMCQ4 was used that contained primer sites for the cytokines under investigation. Plasmids were kindly provided by MF Kagnoff, Department of Medicine, Univer-

sity of California, San Diego. Using the same primer set, rtPCR of the standard RNA produces a PCR product of a different size to that of the target tissue, thus allowing quantification of specific cytokine mRNA transcripts. PCR products were electrophoresed on agarose gels and bands were visualized by ethidium bromide staining. Band intensities were quantified by densitometry, and RNA quantified from the ratios of band intensities from standard RNA and target RNA.

**Statistics**


Chi-squared analysis was used for comparison of the distribution of histological grades of rejection between groups. Cytokine mRNA data were compared using Cuzick's test for trend.

**Table 1.** Samples suitable for histological analysis


Mouse strain		Number of grafts				
Graft	Recipient	Day 2	Day 4	Day 5	Day 6	Day 9
129SV $+/+$	Balb/c	3	3	4	3	6
129SV $-/-$	Balb/c			10		11
129SV $-/-$	129SV $-/-$			6		8

**Results**

One hundred and thirty-eight grafts were implanted, of which 126 (91%) were subsequently identified and retrieved for analysis. Fifty-four out of 65 (83%) samples intended for histological analysis were adequate for this purpose (19 129SV $+/+$   $\rightarrow$  Balb/c, 21 129SV $-/-$   $\rightarrow$  Balb/c, and 14 129SV $-/-$  isografts). The ones which were not adequate were those in which there was no detectable



**Figure 1.** (a) 'Normal' grade (Ferguson & Parrott 1973) foetal intestinal mucosa. Mucosal architecture is preserved. 129SV $-/-$  graft  $\rightarrow$  129SV $-/-$  host. 9 days post implantation. Original magnification  $\times 400$ . (b) 'Flat' grade (Ferguson & Parrott 1973) enteropathy with subtotal villous atrophy. There is loss of villi and lengthening of crypts. 129SV $-/-$  graft  $\rightarrow$  Balb/c host. 9 days post implantation. Original magnification  $\times 400$ . (c) 'Submucosa' grade (Ferguson & Parrott 1973) enteropathy with complete mucosal destruction. Necrotic tissue is seen overlying the muscularis mucosa. 129SV $+/+$  graft  $\rightarrow$  Balb/c host. 5 days post implantation. Original magnification  $\times 400$ .



**Figure 2.** (a) 129(S)V<sup>+/+</sup> grafts implanted into Balb/c mice: mucosal rejection process at intervals to 9 days post implantation. Mucosal injury varied from none ('normal') to complete destruction ('submucosa') (Ferguson & Parrott 1973). Intermediate grades 'L+', 'L++', and 'flat' indicated lamina propria lymphocytic infiltration, reduction in villous height, and subtotal villous atrophy with crypt hyperplasia, respectively. (b) 129(S)V<sup>-/-</sup> grafts implanted into Balb/c mice: mucosal rejection process at 5 and 9 days post implantation. Histological grading as described by Ferguson & Parrott (1973). (c) 129(S)V<sup>-/-</sup> grafts implanted into 129SV<sup>-/-</sup> mice: mucosal rejection process at 5 and 9 days post implantation. Histological grading as described by Ferguson & Parrott (1973).

graft tissue, presumably because of problems during implantation. The combinations of strains used, the number of grafts analysed, and time points of analysis are summarized in Table 1

A 9-day study period was chosen, based on previous data in which complete loss of mucosa occurred in H-2 genetically mismatched grafts by that time (Ferguson & Parrott 1973). The time course of the rejection process was plotted in the experiments with 129SV<sup>+/+</sup> allografts implanted into Balb/c recipients, and 5 days was chosen as an intermediate time point for subsequent studies.

In the 129SV<sup>+/+</sup>→Balb/c experiments, complete rejection occurred by day 9 with complete loss of mucosa, and intermediate stages of rejection at earlier time points (Figs 1 and 2). In the IFN- $\gamma$  receptor knockout experiments (129SV<sup>-/-</sup>→Balb/c) rejection also occurred, but to a lesser degree, by 9 days, with the majority of grafts displaying subtotal villous atrophy. Iso-graft control 129SV<sup>-/-</sup>→129SV<sup>-/-</sup> were nearly all normal, although at each time point there was some injury, probably due to the grafting procedure. Comparison of the three experimental groups revealed significant differences in the degree of mucosal injury at 5 days ( $\chi^2 = 30.38$ ,  $P = 0.0002$ ) and 9 days ( $\chi^2 = 39.08$ ,  $P < 0.0001$ ) post implantation. Comparison of the two allograft groups revealed a reduction in the degree of mucosal injury with the IFN- $\gamma$  receptor knockout grafts compared to the 'wild type' grafts at 5 days ( $\chi^2 = 10.08$ ,  $P = 0.007$ ) and 9 days post implantation ( $\chi^2 = 13.25$ ,  $P = 0.004$ )

rtPCR analysis was conducted at 9 days post implantation, when the greatest histological differences were noted in the rejection process between the three groups of experiments. Graft tissue was analysed in 5129SV<sup>+/+</sup>→Balb/c, 7129SV<sup>-/-</sup>→Balb/c, and 8129SV isografts. In the two allograft groups (129SV<sup>+/+</sup>→Balb/c and 129SV<sup>-/-</sup>→Balb/c) there was a marked inflammatory response with the cytokines IFN- $\gamma$  and TNF $\alpha$ , but no IL-4 response (Table 2). No IFN- $\gamma$ , TNF $\alpha$  and IL-4 transcripts were detected in the isografts. However there were significantly fewer TNF $\alpha$  transcripts in the allografts from IFN- $\gamma$  receptor knockout mice than in allografts from wild type mice. IFN- $\gamma$  transcripts were also reduced, but due to wide variation in the samples did not reach statistical significance.

## Discussion

Histological examination of intestinal grafts from genetically mismatched donor and hosts (129SV<sup>+/+</sup>→Balb/c)

revealed as expected a time-dependent rejection process, with enteropathy progressing to complete mucosal destruction (Ferguson & Parrott 1972). In genetically similar mice (129SV-/- $\rightarrow$ 129SV-/-), grafts were not rejected and appeared normal. Implantation of foetal gut from IFN- $\gamma$  receptor knockout mice into a genetically dissimilar host (129SV-/- $\rightarrow$ Balb/c) also resulted in rejection of the grafts, with partial or complete villous atrophy by 5 days post implantation, but no further change by 9 days. Our data have demonstrated that IFN- $\gamma$  has, at least, a partial role in the enteropathic process in this model. Quantitative rtPCR for cytokine mRNA confirmed an IFN- $\gamma$  response in the rejection process in both allograft models, which is to be expected since the infiltrating recipient T cells are immunologically normal. Protective effects of the absence of IFN- $\gamma$  receptor expression are therefore not due to host T cell recognition of the grafts, but to events further downstream. In the graft gut both epithelial cells and immune cells of graft origin were present. Foetal gut is immunologically immature however, and the degree of rejection in response to IFN- $\gamma$  is likely to have been dependent on the presence or absence of the IFN- $\gamma$  receptor on graft epithelial cells.

In man and animals, transplantation of intestine into a genetically incompatible host results in graft rejection with mucosal enteropathic changes morphologically similar to those in coeliac disease (Cerf-Bensussan *et al.* 1990). We have used a graft rejection model of enteropathy in which the resultant enteropathic changes in the graft have been shown to be T cell dependent (MacDonald & Ferguson 1976). Studies in other animal models of enteropathy, and studies of human pathological specimens, are confounded by the presence of the normal intestinal bacterial flora. In this work we have used foetal small intestine, which has the advantage of being sterile. In addition, foetal mouse small intestine is

immunologically immature and any changes in the graft are therefore the result of host immune rejection mechanisms against the donor tissue.

IFN- $\gamma$  is a glycosylated protein produced by CD4<sup>+</sup> and CD8<sup>+</sup> T cells, and NK cells. It is the major cytokine involved in Th1 T cell responses. IFN- $\gamma$  inhibits Th2 cytokine production, and IL-4 and IL-10 reciprocally inhibit Th1 responses including IFN- $\gamma$  production. IFN- $\gamma$  stimulates T cells and is a powerful macrophage activator. Macrophages, thus activated, exert their tumoricidal, microbicidal and tissue damaging effects by the production of cytokines, including IL-1, TNF- $\alpha$ , IL-6 and IL-8, and increased production of reactive oxygen and nitrogen intermediates such as nitric oxide and hydrogen peroxide. Predictably, IFN- $\gamma$  has no effect on IFN- $\gamma$  receptor deficient cells, such as in IFN- $\gamma$  receptor-knockout mice (Huang *et al.* 1993). In our graft rejection model of enteropathy IFN- $\gamma$ , produced by the host T cells in response to the graft, would therefore have no effect on the graft tissue. However it clearly will have an effect on host cells which non-specifically migrate into the tissues as a consequence of the grafting process. When small intestinal grafts are implanted into the highly vascular sub-capsular region of the kidney, there is rapid revascularization of the tissue from the host. These vascular and endothelial cells will be normal and capable of responding to IFN- $\gamma$  by up-regulating adhesion molecules, thus allowing further extravasation of host T cells and macrophages into the graft. The quantitative changes we observed in this study in terms of reduced injury and lower TNF $\alpha$  transcripts suggests that there is less inflammatory infiltrate into the IFN- $\gamma$  receptor knockout grafts, but this awaits further study.

The mechanism by which IFN- $\gamma$  contributes to the structural changes of crypt hyperplasia and mucosal remodelling, with reduction in villous height, is unknown. IFN- $\gamma$  has diverse effects, including secondary generation of other macrophage-derived cytokines, including TNF $\alpha$ . In studies of normal adult mice, injection of a single dose of TNF $\alpha$  resulted in rapid development of enteropathy, which was enhanced by addition of IFN- $\gamma$  (Garside *et al.* 1993). In a murine model of graft vs. host disease, inhibition of TNF $\alpha$  ameliorated the enteropathy (Brown *et al.* 1999). *In vitro* studies have demonstrated direct TNF $\alpha$ -mediated toxicity to intestinal crypt cells (Garside *et al.* 1993), and TNF $\alpha$  injection into mice results in apoptosis of villus epithelial cells (Guy-Grand *et al.* 1998). TNF $\alpha$  is a prime candidate for immune-mediated injury in the gut and the reduced TNF $\alpha$  mRNA expression in the IFN- $\gamma$  receptor knockout grafts is consistent with this notion. The dramatic clinical effects of TNF $\alpha$  neutralization in inflammatory bowel

**Table 2.** Quantitative rtPCR analysis of cytokine mRNA expression in graft tissue at 9 days post implantation

Graft/ Recipient	n	IFN- $\gamma$	TNF $\alpha$	IL-4
129SV+/+ $\rightarrow$ Balb/c	5	64 000 (0–204 559)	217 960 (44 207–1.53 $\times$ 10 <sup>6</sup> )	0 (0–131 793)
129SV-/- $\rightarrow$ Balb/c	7	42012 (0–0.5 $\times$ 10 <sup>6</sup> )	5584 (0–335 378)	0 (0–27 476)
129SV-/- $\rightarrow$ 129SV-/-	8	0 (0–3752)	0 (0–2064)	0 (0–0)
NS		P=0.02	NS	

Results expressed as number of cytokine RNA transcripts per  $\mu$ g total sample RNA: median (inter-quartile range). Statistics: Cuzick's test for trend applied to the three study groups. NS = not significant.

disease (van Deventer 1999) further emphasizes its crucial role in T-cell mediated gut damage.

The concept of a bystander effect of mucosal T cell activation on gut stromal cells, epithelial cells and mucosal shape, is not new (Elson *et al.* 1977). Recent studies however, have begun to unravel the biochemical basis for this response. There is now increasing evidence that elevated cytokine concentrations in the mucosa up-regulate the production of epithelial growth factors and matrix remodelling enzymes (Bajaj-Elliott *et al.* 1998; Pender *et al.* 1997). In this scenario, it is not the immune cells that damage the gut, but the resident cells themselves. The data contained in this paper are consistent with this notion.

### Acknowledgements

Andrew Veitch was supported by a Robin Brook Fellowship from the Barts Foundation for Research, Lisa Higgins by the Crohns in Childhood Research Association, and Mona Bajaj-Elliott by the Wellcome Trust.

### References

- BAJAJ-ELLIOTT M., BREESE E., POULSOM R., FAIRCLOUGH P.D. & MACDONALD T.T. (1997) Keratinocyte growth factor in inflammatory bowel disease. Increased mRNA transcripts in ulcerative colitis compared with Crohn's disease in biopsies and isolated mucosal fibroblasts. *Am. J. Pathol* **151**, 1469–1476.
- BAJAJ-ELLIOTT M., POULSOM R., PENDER S.L., WATHEN N.C. & MACDONALD T.T. (1998) Interactions between stromal cell-derived keratinocyte growth factor and epithelial transforming growth factor in immune-mediated crypt cell hyperplasia. *J. Clin. Invest* **102**, 1473–1480.
- BROWN G.R., LINDBERG G., MEDDINGS J., SILVA M., BEUTLER B. & THIELE D. (1999) Tumour necrosis factor inhibitor ameliorates murine intestinal graft-versus-host disease. *Gastroenterology* **116**, 593–601.
- CERF-BENSUSSAN N., BROUSSE N., JARRY A. *ET AL.* (1990) Role of in vivo activated T cells in the mechanisms of villous atrophy in humans: study of allograft rejection. *Digestion* **46** (Suppl. 2), 297–301.
- VAN DEVENTER S.J. (1999) Review article: targeting TNF alpha as a key cytokine in the inflammatory processes of Crohn's disease – the mechanisms of action of infliximab. *Aliment Pharmacol. Ther* **13** (Suppl. 4), 3–8.
- DOHI T., FUJIHASHI K., RENNERT P.D., IWATANI K., KIYONO H. & MCGHEE J.R. (1999) Hapten-induced colitis is associated with colonic patch hypertrophy and T helper 2-type responses. *J. Exp Med.* **189**, 1169–1180.
- ECKMANN L., FIERER J. & KAGNOFF M.F. (1996) Genetically resistant (Ityr) and susceptible (Itys) congenic mouse strains show similar cytokine responses following infection with *Salmonella dublin*. *J. Immunol.* **156**, 2894–2900.
- ELSON C.O., REILLY R.W. & ROSENBERG I.H. (1977) Small intestinal injury in the graft versus host reaction: an innocent bystander phenomenon. *Gastroenterology* **72**, 886–889.
- ELVES M.W. & FERGUSON A. (1975) The humoral immune response to allografts of foetal small intestine in mice. *Br. J. Exp Pathol* **56**, 454–458.
- FERGUSON A. & PARROT D.M.V. (1972) Growth and development of 'antigen-free' grafts of foetal mouse intestine. *J. Pathol* **106**, 95–101.
- FERGUSON A. & PARROTT D.M. (1973) Histopathology and time course of rejection of allografts of mouse small intestine. *Transplantation* **15**, 546–554.
- FERREIRA R.C., FORSYTH L.E., RICHMAN P.I., WELLS C., SPENCER J. & MACDONALD T.T. (1990) Changes in the rate of crypt epithelial cell proliferation and mucosal morphology induced by a T-cell-mediated response in human small intestine. *Gastroenterology* **98**, 1255–1263.
- FISH S.M., PROUJANSKY R. & REENSTRA W.W. (1999) Synergistic effects of interferon gamma and tumour necrosis factor alpha on T84 cell function. *Gut* **45**, 191–198.
- GARSDIE P., BUNCE C., TOMLINSON R.C., NICHOLS B.L. & MOWAT A.M. (1993) Analysis of enteropathy induced by tumour necrosis factor alpha. *Cytokine* **5**, 24–30.
- GUY-GRAND D., DISANTO J.P., HENCHOZ P., MALASSIS-SERIS M. & VASSALLI P. (1998) Small bowel enteropathy: role of intra-epithelial lymphocytes and of cytokines (IL-12, IFN-gamma, TNF) in the induction of epithelial cell death and renewal. *Eur J. Immunol.* **28**, 730–744.
- GUY-GRAND D. & VASSALLI P. (1986) Gut injury in mouse graft-versus-host reaction. Study of its occurrence and mechanisms. *J. Clin. Invest* **77**, 1584–1595.
- HALTENSEN T.S., SCOTT H., FAUSA O. & BRANDTZAEG P. (1993) Gluten stimulation of coeliac mucosa in vitro induces activation (CD25) of lamina propria CD4+ T cells and macrophages but no crypt-cell hyperplasia. *Scand. J. Immunol.* **38**, 581–590.
- HUANG S., HENDRIKS W., ALTHAGE A. *ET AL.* (1993) Immune response in mice that lack the interferon-gamma receptor. *Science* **259**, 1742–1745.
- KONTAKOU M., STURGESS R.P., PRZEMIOSLO R.T., LIMB G.A., NELUFER G.M. & CICLITIRA P.J. (1994) Detection of interferon gamma mRNA in the mucosa of patients with coeliac disease by in situ hybridisation. *Gut* **35**, 1037–1041.
- LIONETTI P., BREESE E., BRAEGGER C.P., MURCH S.H., TAYLOR J. & MACDONALD T.T. (1993) T-cell activation can induce either mucosal destruction or adaptation in cultured human fetal small intestine. *Gastroenterology* **105**, 373–381.
- MACDONALD T.T. & FERGUSON A. (1976) Hypersensitivity reactions in the small intestine. 2. Effects of allograft rejection on mucosal architecture and lymphoid cell infiltrate. *Gut* **17**, 81–91.
- MACDONALD T.T. & SPENCER J. (1988) Evidence that activated mucosal T cells play a role in the pathogenesis of enteropathy in human small intestine. *J. Exp Med.* **167**, 1341–1349.
- MARIC D., RIDDELL R.H., STEELE-NORWOOD D., BOROJEVIC R., DRAGOMIR A. & CROITORU K. (1996) Characterisation of enteropathy induced by in vivo T cell activation in Balb/c mice: role of TCR $\alpha/\beta$  and TCR $\gamma/\delta$  T cells. *Gastroenterology* **110**, A957.

- PENDER S.L., LIONETTI P., MURCH S.H., WATHAN N. & MACDONALD T.T. (1996) Proteolytic degradation of intestinal mucosal extracellular matrix after lamina propria T cell activation. *Gut* **39**, 284–290.
- PENDER S.L., TICKLE S.P., DOCHERTY A.J., HOWIE D., WATHAN N.C. & MACDONALD T.T. (1997) A major role for matrix metalloproteinases in T cell injury in the gut. *J. Immunol.* **158**, 1582–1590.
- STROBER W., LUDVIKSSON B.R. & FUSS I.J. (1998) The pathogenesis of mucosal inflammation in murine models of inflammatory bowel disease and Crohn's disease. *Ann. Intern. Med.* **128**, 848–856.
- WAKELIN D., GOYAL P.K., DEHLAWI M.S. & HERMANEK J. (1994) Immune responses to *Trichinella spiralis* and *T. pseudo-spiralis* in mice. *Immunology* **81**, 475–479.

